Description

Arrowhead Pharmaceuticals: Its Efforts Towards Plozasiran Development & Commercialization 

Arrowhead Pharmaceuticals has reported its financial results for fiscal 2024 alongside a strategic collaboration with Sarepta Therapeutics. The partnership marks a significant realignment in Arrowhead’s business model, focusing on delivering balance through collaboration on non-core assets while redirecting resources toward wholly-owned programs, primarily in the cardiometabolic space. The deal with Sarepta is projected to potentially exceed $11 billion, encompassing both upfront and milestone payments. Arrowhead receives an immediate cash infusion of $500 million, alongside $325 million through Sarepta’s equity purchase at a premium rate. Additional yearly installments and milestone payments, depending on the phased progress of certain projects, promise further financial inflows, securing funding through 2028 with potential commercialization milestones within reach.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!